Cyclic guanosine 5'-monophosphate-dependent protein kinase II is induced by luteinizing hormone and progesterone receptor-dependent mechanisms in granulosa cells and cumulus oocyte complexes of ovulating follicles.
Cyclic GMP (cGMP)-dependent protein kinase II (Prkg2, cGK II) was identified as a potential target of the progesterone receptor (Nr3c3) in the mouse ovary based on microarray analyses. To document this further, the expression patterns of cGK II and other components of the cGMP signaling pathway were analyzed during follicular development and ovulation using the pregnant mare serum gonadotropin (PMSG)-human chorionic gonadotropin (hCG)-primed immature mice. Levels of cGK II mRNA were low in ovaries of immature mice, increased 4-fold in response to pregnant mare serum gonadotropin and 5-fold more within 12 h after hCG, the time of ovulation. In situ hybridization localized cGK II mRNA to granulosa cells and cumulus oocyte complexes of periovulatory follicles. In progesterone receptor (PR) null mice, cGK II mRNA was reduced significantly at 12 h after hCG in contrast to heterozygous littermates. In primary granulosa cell cultures, cGK II mRNA was induced by phorbol 12-myristate 13-acetate enhanced by adenoviral expression of PR-A and blocked by RU486 and trilostane. PR-A in the absence of phorbol 12-myristate 13-acetate was insufficient to induce cGK II. Expression of cGK I (Prkg1) was restricted to the residual tissue and not regulated by hormones. Guanylate cyclase-A (Npr1; GC-A) mRNA expression increased 6-fold by 4 h after hCG treatment in contrast to pregnant mare serum gonadotropin alone and was localized to granulosa cells of preovulatory follicles. Collectively, these data show for the first time that cGK II (not cGK I) and GC-A are selectively induced in granulosa cells of preovulatory follicles by LH- and PR-dependent mechanisms, thereby providing a pathway for cGMP function during ovulation.
Sriraman
Venkataraman
V
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Rudd
Michael D
MD
Lohmann
Suzanne M
SM
Mulders
Sabine M
SM
Richards
JoAnne S
JS
D000818:Animals; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D062967:Cyclic GMP-Dependent Protein Kinase Type II; D017869:Cyclic GMP-Dependent Protein Kinases / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology; D006107:Granulosa Cells / Q000737:chemistry / Q000201:enzymology*; D006162:Guanylate Cyclase / Q000378:metabolism; D007986:Luteinizing Hormone / Q000494:pharmacology*; D051379:Mice; D015735:Mifepristone / Q000494:pharmacology; D009865:Oocytes / Q000737:chemistry / Q000201:enzymology; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects*; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D012333:RNA, Messenger; D011980:Receptors, Progesterone; D015735:Mifepristone; D007986:Luteinizing Hormone; D062967:Cyclic GMP-Dependent Protein Kinase Type II; D017869:Cyclic GMP-Dependent Protein Kinases; C569729:PRKG2 protein, human; C569730:Prkg2 protein, mouse; D006162:Guanylate Cyclase; D013755:Tetradecanoylphorbol Acetate